Cited 3 times in
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.